Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes

Clinical and Experimental Medicine

Volumn 15, Issue 1, 2015, Pages 73-83

  Filip, Agata A ^a   Ciseł, Bogumiła ^a   Wąsik Szczepanek, Ewa ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Apoptosis; CLL; Gene expression profiling; Microenvironment; Nurse like cells

Indexed keywords

BCL2 RELATED PROTEIN A1; CHLORAMBUCIL; DEXAMETHASONE; PROTEIN BCL 2; STROMAL CELL DERIVED FACTOR 1; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; BCL2 PROTEIN, HUMAN; BCL2-RELATED PROTEIN A1; CXCL12 PROTEIN, HUMAN; XIAP PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CELL CONTACT; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LEUKEMIA CELL; MALE; MICROENVIRONMENT; NURSE LIKE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; B LYMPHOCYTE; BYSTANDER EFFECT; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; B-LYMPHOCYTES; BYSTANDER EFFECT; CELL SURVIVAL; CHEMOKINE CXCL12; CHLORAMBUCIL; COCULTURE TECHNIQUES; DEXAMETHASONE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MONOCYTES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84921911884     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-013-0268-z     Document Type: Article

References (35)

1. Müller-Hermerink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H (2008) Chronic lymphocytic leukaemia/small lymphocytic leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, pp 180–182
2. Deaglio S, Malavasi F (2009) Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 94:752–756
3. Ponzoni M, Doglioni C, Caligaris-Cappio F (2011) Chronic lymphocytic leukemia: the pathologist’s view of lymph node microenvironment. Semin Diagn Pathol 28:161–166
4. Hendrix TM, Chilukuri RV, Martinez M, Olushoga Z, Blake A, Brohi M, Walker C, Samms M, Guyden JC (2010) Thymic nurse cells exhibit epithelial progenitor phenotype and create unique extra-cytoplasmic membrane space for thymocyte selection. Cell Immunol 261:281–292. doi:10.1016/j.cellimm.2009.11.004
5. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquilla M, Kipps TJ (2000) Blood derived nurse cells protect leukemia B cells from spontaneous apoptosis through stromal-cell derived factor-1. Blood 96:2655–2663
6. Tsukada N, Burger AJ, Zvaifler NJ, Kipps TJ (2002) Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood 99:1030–1037
7. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ et al (2009) High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood 113:3050–3058
8. Cols M, Barra CM, He B, Puga I, Xu W, Chiu A, Tam W, Knowles DM, Dillon SR, Leonard JP, Furman RR, Chen K, Cerutti A (2012) Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol 188:6071–6083. doi:10.4049/jimmunol.1102066
9. Filip AA, Ciseł B, Koczkodaj D, Wąsik-Szczepanek E, Piersiak T, Dmoszyńska A (2013) Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? Blood Cells Mol Dis 50:263–270. doi:10.1016/j.bcmd.2012.12.003
10. Natoni A, O’Dwyer M, Santocanale C (2013) A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization. Methods Mol Biol 986:217–226. doi:10.1007/978-1-62703-311-4_14
11. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute—working Group 1996 guidelines. Blood 111:5446–5456. doi:10.1182/blood-2007-06-093906
12. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219–234
13. Böyum A (1968) Separation of leukocytes from blood and bone marrow, introduction. Scand J Lab Clin Invest Suppl 97:7
14. Duff MD, Mestre J, Maddali S, Yan ZP, Stapleton P, Daly JM (2007) Analysis of gene expression in the tumor-associated macrophage. J Surg Res 142:119–128
15. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics 19:185–193
16. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563–574. doi:10.1182/blood-2010-05-284984
17. Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D et al (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95:1526–1533
18. Fecteau JF, Kipps TJ (2012) Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed) 4:61–73
19. Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bär C, Dierks C, Pfeifer D, Ott A, Mertelsmann R, Gribben JG, Veelken H, Zirlik K (2010) The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia—CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol 151:167–178. doi:10.1111/j.1365-2141.2010.08316
20. McCaig AM, Cosimo E, Leach MT, Michie AM (2012) Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. PLoS ONE 7:e48929. doi:10.1371/journal.pone.0048929
21. di Celle PF, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, Pini M, Mantovani A, Foa R (1994) Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 84:220–228
22. Poggi A, Prevosto C, Catellani S, Rocco I, Garuti A, Zocchi MR (2010) Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. Br J Haematol 151:252–264. doi:10.1111/j.1365-2141.2010.08343
23. Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D’Arena G et al (2010) CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 16:87–91
24. Smolej L (2013) The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opin Invest Drugs 21:1009–1017
25. Burger JA, Montserrat E (2013) Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121:1501–1509
26. Baptista MJ, Muntañola A, Calpe E, Abrisqueta P, Salamero O, Fernández E, Codony C, Giné E, Kalko SG, Crespo M, Bosch F (2012) Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status. Clin Cancer Res 18:5924–5933. doi:10.1158/1078-0432.CCR-11-2771
27. Shaw RK, Boggs DR, Silberman HR, Frei E (1961) A study of prednisone therapy in chronic lymphocytic leukemia. Blood 17:182–195
28. Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88:803–816
29. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214–5218
30. Aqeilan RI, Calin GA, Croce CM (2012) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17:215–220. doi:10.1038/cdd.2009.69
31. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488–496. doi:10.1200/JCO.2011.34.7898
32. Davids MS, Letai A, Brown JR (2013) Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma 54:1823–1825. doi:10.3109/10428194.2013.796051
33. Fukuda S, Pelus LM (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5:1087–1098
34. Pasanen AK, Kuitunen H, Haapasaari KM, Karihtala P, Kyllönen H, Soini Y, Turpeenniemi-Hujanen T, Kuittinen O (2012) Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. Leuk Lymphoma 53:624–631. doi:10.3109/10428194.2011.624226
35. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, Yodoi J (1999) Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274:27891–27897